Pharmacist Impact on Treatment Intensification and Hemoglobin A1C in Patients With Type 2 Diabetes Mellitus at an Academic Health Center

Journal of Pharmacy Practice
Kevin Cowart, Karen R Sando

Abstract

Achievement of treatment goals for patients with type 2 diabetes mellitus (T2DM) is suboptimal. This is in part driven by a lack of treatment intensification when warranted, termed "clinical inertia." To investigate time to treatment intensification and changes in A1C among pharmacist-physician managed (PPM) patients compared to usual medical care (UMC) in patients with T2DM. Retrospective matched cohort study at 2 academic family medicine clinics. Patients in each cohort were matched 1:1 based on age (±5 years), primary care provider, gender, and race. A total of 50 patients met inclusion criteria. Mean time to treatment intensification was longer in the UMC cohort as compared with the PPM cohort (325 (66) days vs 200 (62) days [P = .50]). A higher percentage of patients in the PPM cohort achieved ≥0.5% reduction in A1C in comparison to the UMC cohort (60% vs 44%, respectively [P = .41]). Patients in the PPM cohort experienced a greater mean decrease in A1C from baseline when compared to patients in the UMC cohort (-1% (1.8%) vs -0.4% (2.2%) [P = .24]). Patients exposed to a pharmacist in this retrospective matched cohort study experienced shorter time to treatment intensification and a greater reduction in A1C than those mana...Continue Reading

References

Feb 27, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·R W GrantJ B Meigs
Jan 29, 2005·Diabetes Care·Richard W GrantUNKNOWN University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team
Dec 13, 2005·Health Services Research·Dan R BerlowitzAshley T Wong
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
May 11, 2016·Diabetes, Obesity & Metabolism·A Z Fu, J J Sheehan
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Dec 12, 2017·BMJ Open Diabetes Research & Care·Ronald T AckermannDavid T Liss

❮ Previous
Next ❯

Citations

Jun 18, 2020·Journal of Evaluation in Clinical Practice·Ashley H MeredithJasmine D Gonzalvo
May 20, 2020·BMC Health Services Research·Georgios Dimitrios KarampatakisKath Ryan
Nov 9, 2020·Canadian Journal of Diabetes·Paulina K WrzalNoah M Ivers
Jun 29, 2021·Diabetes, Obesity & Metabolism·Rhea E PowellKamlesh Khunti

❮ Previous
Next ❯

Methods Mentioned

BETA
amputations

Software Mentioned

SPSS
Epic

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.